Cargando…
Multiplex Ligation-dependent Probe Amplification Can Clarify HER2 Status in Gastric Cancers with “Polysomy 17”
Therapy with trastuzumab confers a survival benefit in HER2 positive advanced gastric and gastroesophageal adenocarcinoma. HER2 status is evaluated by immunohistochemistry (IHC) and in situ hybridization (ISH). An ISH ratio of HER2 to centromere 17 (CEP17) ≥2.0 is considered amplified. This assumes...
Autores principales: | Wang, Tao, Amemiya, Yutaka, Henry, Pauline, Seth, Arun, Hanna, Wedad, Hsieh, Eugene T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4392047/ https://www.ncbi.nlm.nih.gov/pubmed/25874002 http://dx.doi.org/10.7150/jca.11424 |
Ejemplares similares
-
Added Value of HER-2 Amplification Testing by Multiplex Ligation-Dependent Probe Amplification in Invasive Breast Cancer
por: Kuijpers, Chantal C. H. J., et al.
Publicado: (2013) -
HER-2/neu amplification testing in breast cancer by Multiplex Ligation-dependent Probe Amplification: influence of manual- and laser microdissection
por: Moelans, Cathy B, et al.
Publicado: (2009) -
HER-2/neu Amplification Testing in Breast Cancer by Multiplex Ligation-Dependent Probe Amplification in Comparison with Immunohistochemistry and In Situ Hybridization
por: Moelans, Cathy B., et al.
Publicado: (2009) -
Multiplex Ligation-Dependent Probe Amplification to Detect HER2 Amplification in Breast Cancer: New Insights in Optimal Cut-Off Value
por: Moelans, Cathy B., et al.
Publicado: (2010) -
HER2, chromosome 17 polysomy and DNA ploidy status in breast cancer; a translational study
por: Halilovic, Altuna, et al.
Publicado: (2019)